Healthcare Research on Global Study on Malignant Mesothelioma: Cisplatin and Combination Segment Projected to be the Second Most Lucrative Segment by Drug Type
"Global
Market Study on Malignant Mesothelioma: Cisplatin and Combination
Segment Projected to be the Second Most Lucrative Segment by Drug
Type"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
.
.
Description-
'
'
--
An introduction to the report --
All the information pertaining to the market of
this rare form of cancer is provided in our recently published
report“Malignant Mesothelioma Market: Global Industry
Analysis (2012-2016) and Forecast (2017-2025).” Caused
due to the exposure to toxic asbestos, the occurrence of this cancer
is higher in countries such as Russia and China. These two countries
are pegged to represent the most lucrative markets, owing to the
relatively high production of asbestos in these countries. Besides, a
high consumption of asbestos in the APAC region is expected to create
a sizeable opportunity for key players in this market.
Get
Sample
Report
@
https://www.researchmoz.us/enquiry.php?type=S&repid=1396725
'
'
--
Our
analysts have observed that the rapid substitution through generics
to ease availability and affordability is the key focus area in the
global malignant mesothelioma market. We have observed that the
application of combination therapies is gaining traction in the
market across regions. Documented evidence on the adoption of
combination treatments and benefits is being made available to ease
patients’ journey through the treatment process. According to our
analysts, there is a great need in the market to efficiently meet the
requirements for the present treatment regimen. The drugs that are
currently in use do not show much response rates. The malignant
mesothelioma treatment market requires drugs to increase the current
survival rate.
--
Acquisitions and collaborations are
the key strategies adopted by players to develop molecules for the
better treatment of malignant mesothelioma. Companies are focusing on
collaborating with established research centers and other cancer drug
manufacturers to develop drugs. Our research indicates that the
hospital pharmacies distribution channel segment is expected to
witness a significant rise in revenue share over the forecast period,
owing to the increasing direct procurement of mesothelioma drugs by
governments to ensure availability in hospital pharmacies and
oncology centers.
--
We have used our in-house
epidemiology data based model to estimate the global malignant
mesothelioma market numbers
--
Weighted average selling price has been considered
to estimate the market size of various drugs mentioned in the scope
of the study. Price per country is captured with the local currency.
The local currency figures are then converted to USD to offer
forecasts in a consistent currency standard. We have also considered
the latest annual exchange rate to reflect the impact of the most
recent economic conditions. Prices considered in the models are
standardized based on the average dosage used per malignant
mesothelioma treatment per dosage cycle of six months. Availability
of branded off-patent equivalents has been taken into consideration
while calculating prices. We have adopted the bottom-up approach to
forecast the malignant mesothelioma market globally. Besides this,
forecasting is done using our internal proprietary model that
considers different macro-economic factors, industry based demand
driving factors impacting the market and the relevant forecast trends
apart from disease related factors.
--
Market Taxonomy
--
--
Drug Type
- Pemetrexed
- Cisplatin
- Carboplatin
- Gemcitabine
- Vinorelbine
- Others
--
Route of Administration
- Oral
- Parenteral
--
Region
- North America
- Latin America
- Europe
- APAC
- MEA
--
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Oncology Centers
--
Research Methodology
--
Our research methodology leverages both primary
and secondary research to collect the relevant market data. We have
analyzed the global malignant mesothelioma market by considering key
player revenue, usage patterns, historic trends, and problems faced
by oncologists, the required treatment developments, and most
preferred drugs. Key opinion leaders including experienced healthcare
professionals in various healthcare facilities at the country level
have been considered for primary research. These estimates have been
further validated with drug manufacturers, distributors, and
suppliers. Extensive secondary research has been carried out to
understand the epidemiology of malignant mesothelioma, treatment
rate, adoption rate, regulatory scenarios, average selling price and
the global reimbursement scenario by referring to published
scientific literature from various databases such as the WHO,
Asbestos.com, PubMed, Springer, and Wiley among many others. We have
also analyzed the various companies’ annual reports, investor
presentations, SEC filings, reports and press releases to fetch
substantial information pertaining to the market size, trends,
opportunities, drivers, and restraints.
.
.
Comments
Post a Comment